Peptone

Executive Summary

Peptone is a London-based pre-clinical biotech company pioneering the use of AI and machine learning to discover small-molecule therapeutics against intrinsically disordered proteins (IDPs), a class of targets traditionally considered undruggable. By combining bespoke mass spectrometry, next-generation ML, and protein disorder expertise, Peptone aims to model and drug IDPs implicated in various diseases. Founded in 2017, the company operates at the intersection of AI, proteomics, and drug discovery, and is currently in the pre-clinical stage with no disclosed funding or valuation. While the field of IDP targeting is nascent and high-risk, Peptone’s unique technology platform and focus on an underserved target class could position it as a leader if it achieves proof-of-concept. The company’s progress will depend on securing partnerships or funding to advance its pipeline towards clinical development.

Upcoming Catalysts (preview)

• Q4 2026Series A Funding Announcement60% success
• Q2 2027Preclinical Validation Data for Lead Program50% success
• H1 2027Pharma Partnership for IDP Platform30% success